), a medical technology company, announced the voluntary recall of
its Alaris Pump Module, Model 8100. The recalled lot was
manufactured between October 2011 and February 2012.
The product recall was issued due to a latent risk which might
cause the door keypad overlay of the pump module to separate from
the keypad assembly. It was seen to be a flaw which could lead to
detrimental and fatal consequences.
As per the U.S. Food and Drug Association (FDA), this voluntary
product recall is a Class 1 recall. A Class 1 recall is specified
as the recall of a product having a considerable probability of
serious adverse health or fatal consequences associated with the
use of defective units.
The company notified that the door assembly of the related pump
modules will be substituted within a period of 60 days. Meanwhile,
consumers have been advised to visually monitor the pump module
keypad overlay for any explicit indication of overlay
Product recall woes at CareFusion continue. Earlier this year,
the company initiated a voluntary recall of its EnVe ventilators
and AirLife Infant Breathing Circuit in July and May, respectively.
The voluntary recall of EnVe ventilators applies to those
manufactured between December 2010 and January 2012.
With regard to AifLife Infant Breathing Circuit, the company
found that the equipment sub-part known as an adapter manufactured
between June 1, 2010, and February 3, 2012, had on occasion
developed a crack during patient use. It had resulted in leakage
and loss in the intended tidal volume.
Amidst safety concerns and manufacturing defects associated with
its products, concerns about CareFusion's production capabilities
have also grown. It has to be accepted that this could lead
to a loss in consumer confidence and trust. The costs associated
with the recalls and remediation plans is also a matter of concern
for the company.
CareFusion is a medical technology company with a global
presence. It also plans to extend its international footprint. The
company is committed to boosting its bottom-line on the back of
portfolio innovation and enhancement and operational efficiencies.
Helped by a diversified revenue base of industry leading offerings,
the company is well poised to accelerate growth.
It competes with
Baxter International Inc.
Becton, Dickinson and Company
) in certain niches.
CareFusion currently retains a Zacks #2 Rank, which translates
into a short-term Buy rating.
BAXTER INTL (BAX): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis
CAREFUSION CORP (CFN): Free Stock Analysis
OMNICELL INC (OMCL): Free Stock Analysis Report
To read this article on Zacks.com click here.